



ENS@T was founded in 2002 by putting together three already existing National Adrenal Networks (Comete in France, GANIMED in Germany, and NISGAT in Italy) and teams from the United Kingdom all dedicated to the study of adrenal tumours. In 2009, ENS@T became a membership-based society with statutes and bye-laws and a large number of European clinicians and scientists have joined in the efforts of the Network by becoming members of ENS@T.



The European Science Foundation (ESF) provides a platform for its Member Organisations to advance European research and explore new directions for research at the European level. Established in 1974 as an independent non-governmental organisation, the ESF currently serves 75 Member Organisations across 30 countries.

9th Scientific Meeting of the European Network for the Study of Adrenal Tumours (ENS@T) *Turin, November 26–27, 2010*

Venue: San Luigi Hospital, Regione Gonzole 10
10043 Orbassano (Turin) - Italy



Friday, November 26

13.00 - Get together and Welcome Buffet

13.45 - Introduction

Session I (14.00 – 15.30) - Update on current projects from ENS@T members on ACC (chaired by B. Allolio)

14.00-14.15: COMBINED TREATMENT MITOTANE/IONIZING RADIATIONS INHIBITS THE TUMOR GROWTH IN A XENOGRAFT MODEL OF ADRENOCORTICAL CARCINOMA. Stigliano A, Cerquetti L, Porcelli T, Sampaoli C, De Salvo M, Bucci B, Argese N, De Venanzi A, Carpinelli G, Rindi G, Toscano V.

14.15-14.30: PRELIMINARY STUDIES ON MITOTANE MECHANISM OF ACTION IN IN VITRO AND IN VIVO MODELS OF ACC.

Poli G, Luconi M, Mangoni M, Canu L, Gabriella Nesi G, Francalanci M, Cantini G, Ercolino T, Serio M, Mannelli M.

14.30-14.45: DO MITOTANE LEVELS IMPACT ON THE OUTCOME OF PATIENTS TREATED ADJUVANTLY FOLLOWING RADICAL RESECTION OF AN ADRENOCORTICAL CANCER?

Daffara FC, Leboulleux S, Wortmann S, Zaggia B, Ardito A, De Francia S, Al Ghuzian A, Fassnacht M, Volante M, Berruti A, Allolio B, Baudin E, Terzolo M.

14.45-15.00: DIAGNOSTIC AND PROGNOSTIC VALUE OF GENOME ALTERATIONS IN ADRENOCORTICAL TUMORS.

Assié G, Barreau O, Wilmot Roussel H, de Reyniès A, Tissier F, Bertagna X, Clauser E, Bertherat J.

15.00-15.15: SUNITINIB IN REFRACTORY ADRENOCORTICAL CARCINOMA (ACC): RESULTS OF A PHASE II SINGLE ARM OPEN LABEL TRIAL (SIRAC TRIAL).

Kroiss, M, Quinkler M Allolio B, Fassnacht M for the SIRAC investigators.

15.15-15.30: DEVELOPMENT OF A NOVEL ANTI-IGF1-RECEPTOR IMMUNOLIPOSOMAL THERAPY FOR THE TREATMENT OF ENDOCRINE TUMORS.

Hantel C, Lewrick F, Schneider S, Zwermann O, Reincke M, Peschka-Süss R, Beuschlein F.

Session II (15.30-17.00) - Update on current projects from ENS@T members on APA (chaired by F. Mantero)

15.30-15.45: THE TWIK-RELATED ACID-SENSITIVE K⁺ CHANNEL 2 (TASK-2) GENE IS UNDER-EXPRESSED IN ALDOSTERONE-PRODUCING ADENOMA. Lenzini L, Seccia TM, Caroccia B, Skander G, Ferraro S, Recarti C, Pelizzo MR, Pessina AC, Rossi GP.

15.45-16.00: ADRENAL CORTEX REMODELLING AND FUNCTIONAL ZONA GLOMERULOSA HYPERPLASIA IN PRIMARY ALDOSTERONISM. Boulkroun S, Samson-Couterie B, Golib Dzib JF, Lefebvre H, Louiset E, Amar L, Plouin PF, Lalli E, Jeunemaitre X, Benecke A, Meatchi T, Zennaro MC.

16.00-16.15: EVALUATION OF ADRENAL VEIN SAMPLING IN THE GERMAN CONN'S REGISTRY – THERE'S ROOM FOR IMPROVEMENT. Vonend O for the participants of the German Conn's Registry (Ockenfels N, Reincke M, Allolio B, Lang K, Mai K, Quack I, Saleh A, Seufert J, Beuschlein F, Quinkler M, Hahner S, Bindlingmeier M, Lorenz R, Rump LC).

16.15-16.30: MORTALITY IN PRIMARY ALDOSTERONISM IN GERMANY. LESSONS FROM THE GERMAN CONN'S REGISTRY. Reincke M, Fischer E, Gerum S, Merkle K, Schulz S, Meisinger C, Holle R, Quinkler M, Lang K, Beuschlein F, Bidlingmaier M, Endres S for the Participants of the German Conn's Registry.

16.30-16.45: OMENTAL GENE EXPRESSION IN PRIMARY ALDOSTERONISM: ANALYSIS OF CANDIDATE GENES FOR CARDIOMETABOLIC COMPLICATIONS. Ronconi V, Turchi F, di Tizio V, Appolloni G, Boscaro M, Giacchetti G.

16.45-17.00: ALDOSTERONE SYNTHASE INHIBITION WITH LCI699 IN PATIENTS WITH PRIMARY ALDOSTERONISM. Amar L, Azizi M, Menard J, Peyrard S, Watson C, Plouin P-F.

Coffee break and poster viewing (17.00-17.30)

Poster session

1. The importance of monitoring circulating mitotane levels in the management of adrenocortical cancer patients.
Pirro E and Colleagues.
2. Cross-talk between estrogen (E2) and IGFII in adrenocortical tumor cell proliferation.
Sirianni R and Colleagues.
3. Improved survival in patients with stage II adrenocortical carcinoma (ACC) followed prospectively by specialized centers.
Fassnacht M and Colleagues
4. Plasma concentrations of o,p'DDD, o,p'DDA and o,p'DDE as predictors of tumor response to mitotane in adrenocortical carcinoma: results of a retrospective ENS@T multicentre study.
Hermsen IG and Colleagues.
5. Mitotane plasma level quantification: good concordance between two different analytical methods.
De Francia S and Colleagues.
6. Circannual variation of mitotane and its metabolites plasma levels in patients with adrenocortical carcinoma.
Carrella S and Colleagues.
7. Mitotane enhances the cytotoxic effects of Doxorubicin in an adrenocortical carcinoma cell line.
Zatelli MC and Colleagues.
8. Mitotane induces a concentration-dependent impairment of platelet aggregation in patients with adrenocortical carcinoma.
Hahner S and Colleagues.
9. Morphological variants of adrenocortical carcinoma: clinico-pathological correlation.
Volante M and Colleagues.
10. Sorafenib and Everolimus effects in in vitro and in vivo adrenal models.
Mariniello B and Colleagues.
11. Genetic variations in Axin1 gene in adrenocortical tumours
Gueorguiev M and Colleagues.
12. Sorafenib inhibits proliferation and induces apoptosis in human adrenal carcinoma cells in culture.
Germano A and Colleagues.
13. Adrenal Cortical Carcinoma: our experience.
Lombardi CP and Colleagues.
14. Rosiglitazone impairs proliferation of human adrenocortical cancer: preclinical study in a xenograft mouse model.
Poli G and Colleagues.
15. Development and characterisation of patient-individual tumor models for endocrine tumors
Hantel C and Colleagues.
16. Does nephrectomy during radical adrenalectomy for stage I-II adrenocortical cancer affect patient outcome?
Fiori C and Colleagues.
17. Systematic analysis of G protein-coupled receptor gene expression in ACTH-independent macronodular adrenocortical hyperplasia identifies novel targets for pharmacological control of adrenal Cushing's syndrome.
Chabre O and Colleagues.

18. Epidemiological Data from Surgically Treated Adrenal Masses in SPb MAPS Clinic. Shafigullina U and Colleagues.
19. Effect of acute administration of Alprazolam, a benzodiazepine, in patients with subclinical Cushing's syndrome. Giordano R and Colleagues.
20. Adrenal incidentalomas in patients with various malignant diseases: clinical analysis of 2044 patients registered at a single endocrinological center. Kasperlik-Zaluska A and Colleagues.
21. Epidemiological characteristics of incidentally found non-functioning adrenal adenomas in a single tertiary centre Vasilev V and Colleagues.
22. Immunohistochemical characterization of mast cells in aldosterone-producing adenomas. Duparc C and Colleagues.
23. Insulin signaling in adipose tissue of patients with primary aldosteronism. Urbanet R and Colleagues.
24. The Adrenal Vein sampling International Study (AVIS) : an multicentre study on Use and Interpretation of Adrenal Vein Sampling. Rossi GP and Colleagues.
25. Long term modifications of blood pressure and left ventricular geometry in patients with primary aldosteronism after medical and surgical therapy. Cesari M and Colleagues.
26. High expression of the Pro-Renin Receptor in aldosterone producing adenoma causing human primary aldosteronism. Recarti C and Colleagues.
27. A novel SDHD mutation in a patient with multiple paragangliomas and carcinoma of the ascending colon. Elenkova A and Colleagues.
28. Comprehensive genomic characterization of a new form of hereditary pheochromocytoma. Cascon A and Colleagues.
29. Is there still a place for adrenal venous sampling in the diagnostic localization of pheochromocytoma? Därr R and Colleagues.
30. Impact of somatic genetic studies to identify rare functional variants in pheochromocytoma (PHEO) and paraganglioma (PGL). Burnichon N and Colleagues.
31. Novel pathogenetic pathways in adrenocortical and adrenomedullary tumours. Igaz P and Colleagues.
32. Clinical aspects and genetic screening in 98 consecutive patients affected by head and neck paraganglioma (HNPG). Piccini V and Colleagues.
33. Succinate Dehydrogenase Subunit B mutations and malignant pheochromocytoma. Biochemical and functional studies in neuroblastoma SDHB mutated clones. Rapizzi E and Colleagues.

Session III (17.30-19:00) - Update on current projects from ENS@T members on PHEO (chaired by P.-F. Plouin)

17.30-17.45: INCIDENTALY DISCOVERED PHEOCHROMOCYTOMAS – VASCULAR AND METABOLIC COMPLICATIONS BEFORE AND AFTER ADRENAL SURGERY.
Gheorghiu ML, Mangalagiu M, Giurcaneanu M, Baciú I, S Radian S, Poiana C, Badiu C, Coculescu M.

17.45-18.00: SDHA IMMUNOHISTOCHEMISTRY TO DETECT SDHA MUTATIONS IN PARAGANGLIOMAS AND PHEOCHROMOCYTOMA.
Korpershoek E, Favier J, Gaal J, Burnichon N, van Gessel B, Oudijk L, Plouin P-F, Dinjens WNM, Gimenez-Roqueplo A-P, de Krijger RR.

18.00-18.15: PHEOCHROMOCYTOMA AND PREGNANCY: A LITERATURE SURVEY.
Gilles R, Roel E, Janssen F, Timmers HJLM, Dubelaar I, Spaanderman M, Lenders JWM.

18.15-18.30: PREVALENCE OF TMEM127 MUTATIONS IN APPARENTLY SPORADIC PHEOCHROMOCYTOMA.
Schiavi F, Taschin E, Bobisse S, Boaretto F, Zovato S, Opocher G.

18.30-18.45: FUNCTIONAL CHARACTERIZATION AND STAGING OF PHEOCHROMOCYTOMA AND PARAGANGLIOMA BY FDG PET.
Timmers HJLM, Chen CC, Carrasquillo JA, Whatley M, Ling A, Eisenhofer G, King KS, Rao JU, Adams KT, Karel Pacak K

18.45-19.00: SUCCINATE DEHYDROGENASE (SDH) MUTATIONS: BIOCHEMICAL AND FUNCTIONAL EFFECTS IN PHEOCHROMOCYTOMA/PARAGANGLIOMA TISSUES.
Rapizzi E, Ercolino T, Canu L, Giaché V, Mannelli M.

Dinner 20.30

Saturday, November 27

General assembly (08.30-9.30)

Session IV (09.30-11.00): Update on current projects from ENS@T members on ACC (chaired by F. Beuschlein)

9.30-9.45: GENETICS AND GENOMICS OF CHILDHOOD ADRENOCORTICAL TUMOURS.

Doghman M, El Wakil A, Letouzé E, Rosati R, Zambetti GP, Figueiredo BC, Lalli E.

9.45-10.00: EXPRESSION OF mRNA STABILITY REGULATORS IS ALTERED IN HUMAN ADRENOCORTICAL CANCER.

Castan-Desroches A, Ciais D, Feige J-J, Cherradi N.

10.00-10.15: LONG-TERM SURVIVAL IN ADRENOCORTICAL CARCINOMA (ACC) WITH ACTIVE SURGERY AND USE OF MONITORED MITOTANE.

Wängberg B, Khorram-Manesh A, Jansson S, Nilsson B, Nilsson O, Lindstedt S and Ahlman H

10.15-10.30: TRANSCRIPTOSOME ANALYSIS REVEALS THAT p53 and β -CATENIN ALTERATIONS OCCUR IN A GROUP OF AGGRESSIVE ADRENOCORTICAL CANCERS.

Ragazzon B, Libe R, Gaujoux S, Assié G, Fassnacht M, Fratticci A, Launay P, Clouser E, Bertagna X, Tissier F, de Reyniès A, Bertherat J.

10.30-10.45: MUTATIONAL ANALYSES OF EGFR AND DOWNSTREAM PATHWAYS IN ADRENOCORTICAL CARCINOMA; CORRELATION WITH MITOTANE RESPONSE AND SURVIVAL.

Hermesen IGC, Haak HR, de Krijger R, Kerkhofs TMA, Feelders RA, de Herder W, Wilmink JW, Smit JWA, de Miranda NF, van Eijk R, van Wezel T, Morreau H.

10.45-11.00: ADRENOCORTICAL TUMORS: EVALUATION AND HARMONIZATION OF THE WEISS SYSTEM CRITERIA AT THE FRENCH LEVEL.

Tissier F, Aubert S, Leteurtre E, Alghuzlan A, Patey M, Decaussin M, Doucet L, Gobet F, Hoang C, Mazerolles C, Monges G, Sturm N, Renaudin K, Vacher-Lavenu MC, Viallon V, Baudin E, Bertagna X, Coste J, Libé R.

Coffee break and poster viewing (11.00 – 12.00)

Session V (12.00-13.20): Proposal for future ENS@T projects Groups (chaired by M. Reincke)

12.00-12.20: THE ENS@T ONLINE REGISTRY – DEVELOPMENT AND USE.
Stell A.

12.20-12.40: PROPOSAL OF A PROSPECTIVE STUDY ON SUBCLINICAL CUSHING'S SYNDROME IN PATIENTS WITH ADRENAL INCIDENTALOMA.
Tabarin A, Terzolo M, Allolio B.

12.40-13.00: SECONDACT: TREATMENT OF ADVANCED ACC BEYOND FIRMACT.
Baudin E, Haak H

13.00-13.20: THE "EURINE ACT" PROJECT.
Arlt W

13.30 – End of Meeting

ENS@T Steering committee meeting / ESF meeting in parallel (14.00 – 16.00)

The meeting was funded by the European Science Foundation, HRA Pharma, OSI Pharma and the Italian Ministry of Scientific Research (PRIN grant n° 20085P5S49)